Overview

Neoadjuvant Therapy of SBRT Sequencial with Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC Patients(neoR-TORCH)

Status:
RECRUITING

Trial end date:
2029-06-01

Target enrollment:

Participant gender:

Summary

This is a randomized, controlled, multi-center, phase III clinical study to evaluate the efficacy and safety of SBRT sequencial with Toripalimab and chemotherapy versus Toripalimab and chemotherapy for subjects with resectable, stage II-III NSCLC.

Phase:

PHASE3

Details

Lead Sponsor:

Shanghai Chest Hospital

Treatments:

toripalimab